

19 November 2018

ASX Code: MXC

## Agreement signed with renowned research universities to launch CannaHub

An international research hub formed for the development of world leading medicinal cannabis research, technologies and innovations

### Highlights

- MXC has signed a partnership agreement with the Royal Melbourne Institute of Technology (RMIT) and The Hebrew University of Jerusalem (HUJ) to create and launch 'CannaHub', an international research hub for medicinal cannabis and its future applications in the field of medicine and patient treatment
- CannaHub is a new addition to the MXC projects currently underway with RMIT, and will be formally launched in Q1 2019
- CannaHub's research projects will initially focus on the use of medicinal cannabis in the treatment of cancer, the effectiveness of traditional and medicinal cannabis combination treatments and drug delivery systems
- Partnering with world renowned Hebrew University of Jerusalem in a research collaboration project further strengthens the Company's business strategy to become a leading bio-pharma, and product development company
- Represents a key milestone for the Company as CannaHub will act as MXC's primary research and new product development engine, supporting its seed-to-pharma business model through the innovation and development of new medicinal cannabis products and technologies
- All findings, outcomes and conclusions remain the property of CannaHub partners MXC, RMIT and HUJ
- MXC holds the first right to use or acquire all data, technology, or findings generated from CannaHub with potential commercial applications

**MGC Pharmaceuticals Ltd (ASX: MXC or "the Company")** is pleased to announce it has signed a binding partnership agreement with the Royal Melbourne Institute of Technology and The Hebrew University of Jerusalem to form a joint international medical research hub for medicinal cannabis innovation and technologies.

As an extension to MXC existing collaboration with RMIT, the new research hub, to be known as 'CannaHub', is a collaborative centre between MXC, RMIT and HUJ and will be an international shared library of research, data and analytics on medicinal cannabis and its uses including future medical applications and treatments.

CannaHub's research projects will initially focus on 3 key areas in the use of medicinal cannabis, being the treatment of cancer, the effectiveness of traditional and medicinal cannabis combination treatments and drug delivery systems with technological elements. Results from the research project will strategically position the Company as a leader in the cancer research and technology-based drug delivery space, enabling MXC to develop and leverage its commercial IP for the production of new medicinal cannabis products, applications and technologies.

The agreement represents a landmark achievement for MXC. The formation of CannaHub is the first time RMIT or HUI has partnered with a private company to form a research institute in this sector.

CannaHub will become the primary R&D engine for MXC as partnering with research departments of such high calibre supports its growth strategy of becoming a leading pure bio-pharma company with a fully integrated seed-to-pharma business model.

Research departments at other leading medical research universities and related industry bodies will be invited and incentivised to join CannaHub by student exchange programs, royalty payments, availability of infrastructure and the potential to secure funding. By joining, the universities will be given the opportunity to share and participate in a ground-breaking medicinal cannabis research project focussed on the potential uses of cannabis as a treatment for a range of medical conditions.

All outcomes, conclusions and intellectual property will be wholly-owned by CannaHub and under the partnership agreement. Importantly, MXC holds first right to use or acquire data or technology created, or on any findings or innovations generated, that could deliver a potential commercial outcomes from future medical applications and treatments.

### Roby Zomer, Co-founder and Managing Director, MGC Pharmaceuticals commented

"We are very pleased to announce the completion of our formal collaboration and partnership agreement with RMIT and HUI to launch CannaHub. CannaHub is designed to advance world leading research and push forward innovation within the medicinal cannabis pharmaceutical market. We look forward to working with the teams at RMIT and HUI and delivering ground breaking results in the future."

--Ends--

#### For further information, please contact:

**Media Enquiries**

Justin Kelly  
Media and Capital Partners  
+61 408 215 858  
[Justin.Kelly@mcpartners.com.au](mailto:Justin.Kelly@mcpartners.com.au)

**MGC Pharmaceuticals Ltd**

Brett Mitchell  
Executive Chairman  
+61 8 6382 3390  
[info@mgcpharma.com.au](mailto:info@mgcpharma.com.au)

## About MXC

MGC Pharmaceuticals Ltd (ASX: MXC) is an EU based BioPharma company with many years of technical clinical and commercial experience in the medical cannabis industry. The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality Cannabinoids based pharmaceuticals products for the growing demand in the medical markets in Europe, North America and Australasia.

Follow us through our social media channels   